repository
BROWSE
Cited 0 times in 
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
- Authors
- Sim, SH | Kim, JE | Kim, MH | Park, YH | Kim, JH | Suh, KJ | Koh, SJ | Park, KH | Kang, MJ | Ahn, MS | Lee, KE | Kim, HJ | Ahn, HK | Kim, HJ | Park, KU | Byun, JH | Park, JH | Lee, GW | Lee, KS | Sohn, J | Jung, KH | Park, IH
- Citation
- Breast (Edinburgh, Scotland), 65. : 172-178, 2022
- Journal Title
- Breast (Edinburgh, Scotland)
- ISSN
- 0960-97761532-3080
- Abstract
- We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma(R), in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.
- MeSH
- PMID
- 36029565
- Appears in Collections:
- Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
- Ajou Authors
- 안, 미선
- Full Text Link
- Files in This Item:
- 36029565.pdfDownload
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
-
- License
